Skip to main content
. Author manuscript; available in PMC: 2020 Jul 15.
Published in final edited form as: Cell Rep. 2020 Feb 4;30(5):1385–1399.e7. doi: 10.1016/j.celrep.2020.01.020

Figure 3. Mre11 Suppresses Oncogenic Proliferation in pMMECs Independently of Trp53 and ATM.

Figure 3.

(A) Graphic representing how pMMECs are harvested from the mice and manipulated in vitro to assess growth rates.

(B) Description of compound transgenic mice used for pMMEC experiments and resulting genotypes after introduction of Cre recombinase.

(C) pMMEC growth curves examining the effect of Myc overexpression and/or Mre11 hypomorphic mutation. Cell counts are normalized to their respective day 0 counts.

(D) Significant effect of Mre11 mutation on oncogenic growth induced by Myc overexpression or Rb1 deletion in p53-deficient pMMECs. Cell counts are normalized to their respective day 0 counts.

(E) ATM inhibitor Ku55933 does not phenocopy the growth-stimulating effects of Mre11 mutation in Rb1−/−Trp53−/− pMMECs. Statistical significance in (C)–(E) was determined by two-tailed t test on log-transformed data comparing day 12. The p values were adjusted for multiple comparisons by the method of Holm-Sidak. Data are represented as mean ± SEM.

See also Figure S3.